First-in-Human Study of an Oral Formulation of the GLP-1/GIP Co-Agonist VK2735 in Healthy Adults

被引：0
|
作者：
Neutel, Joel
Rowland, Angela
Bell, Francesca
Rooney, Carmela
Rask, Chris
Steele, Becky
Ji, Summer
Barker, Geoff
Mancini, Marianne
Lian, Brian
机构：
来源：
OBESITY | 2024年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Poster-017
引用
收藏
页码：61 / 62
页数：2
相关论文
共 50 条
  • [11] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Nauck, Michael A.
    D'Alessio, David A.
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [12] Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study
    Gasiorek, A.
    Heydorn, A.
    Kirkeby, K.
    Key, C.
    Toubro, S.
    Schefe, L. H.
    Dahl, K.
    Hjerpsted, J. B.
    Vegge, A.
    DIABETOLOGIA, 2024, 67 : S42 - S43
  • [13] A Phase 1, Dose-Escalation Study of a Novel dual GIP and GLP-1 receptor agonist (HS-20094) in Healthy Chinese Subjects
    Xie, R.
    Junyu, X.
    Lu, C.
    Yimin, C.
    Xia, Z.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [14] LAPS GLP/GCG Dual Agonist, HM12525A, Confirmed Prolonged Pharmacokinetics in Healthy Volunteers: A First-in-Human Phase 1 Study
    Kang, Jahoon
    DIABETES, 2015, 64 : A46 - A46
  • [15] First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects
    Zhang, Hong
    Li, Qianqian
    Chen, Hong
    Guo, Lingfeng
    Li, Jing
    Xie, Can
    Yan, Jiangyu
    Ding, Yanhua
    BIODRUGS, 2025, : 477 - 486
  • [16] Safety and Pharmacokinetics of AZD9550, a GLP-1R/GCGR Dual Agonist, in a First-in-Human Study
    Sulentic, Petra
    Will, Sarah
    Daniels, Samuel
    Genapathy, Sivaneswary
    Naylor, Jacqueline
    Barbour, April
    Yu, Hongtao
    Boca, Simina
    Carlsson, Elin
    Gopel, Sven
    Hornigold, David
    Oldham, Stephanie
    Robertson, Darren
    Jermutus, Lutz
    Karimi, Mahssa
    Hansen, Lars
    OBESITY, 2024, 32 : 161 - 162
  • [17] Unchanged, but correlated secretion of the incretin hormones GIP and GLP-1 after oral glucose in first degree relatives of Type 2 diabetic patients and healthy subjects
    El-Ouaghlidi, A
    Meier, JJ
    Gabrys, B
    Huecking, K
    Holst, JJ
    Deacon, CF
    Gallwitz, B
    Schmidt, WE
    Nauck, MA
    DIABETOLOGIA, 2002, 45 : A216 - A216
  • [18] Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
    Friedrichsen, Martin Haljeta
    Endahl, Lars
    Kreiner, Frederik Flindt
    Goldwater, Ronald
    Kankam, Martin
    Toubro, Soren
    Nygard, Sune Boris
    MOLECULAR METABOLISM, 2023, 78
  • [19] Development of a sensitive LC-MS/MS assay to support human microdose study for an oral agonist of the GLP-1 receptor
    Kadar, Eugene P.
    Eng, Heather
    Kalgutkar, Amit S.
    Holliman, Christopher L.
    Steeno, Gregory S.
    BIOANALYSIS, 2024, 16 (11) : 545 - 555
  • [20] Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist
    Haggag, Amina Z.
    Xu, Jianfeng
    Butcher, Laurie
    Pagnussat, Sandra
    Davies, Graeme
    Lundqvist, Sara
    Wang, Wenyu
    Van Zuydam, Natalie
    Nelander, Karin
    Jha, Aruni
    Yu, Hongtao
    Boianelli, Alessandro
    Lindmark, Bosse
    Ollerstam, Anna
    Sun, Xuefeng
    Wang, Fan
    Pan, Xiaoliang
    Liu, Haihui
    Chen, Wengang
    Xu, Jianfeng
    Wallenius, Kristina
    Zhou, Jingye
    DIABETES OBESITY & METABOLISM, 2025, 27 (02): : 551 - 562
12345